Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Product revenues	$ 33,300	$ 37,346	$ 19,962
Research and development programs	12,831	23,045	19,788
Total revenues	46,131	60,391	39,750
Costs and operating expenses:
Cost of product revenue	18,179	20,612	6,385
Research and development	48,094	81,680	66,572
Sales, general and administrative	80,733	90,266	62,933
Restructuring charges	4,953	3,514	0
Total costs and operating expenses	151,959	196,072	135,890
Loss from operations	(105,828)	(135,681)	(96,140)
Other income (expense):
Interest and other income, net	929	1,310	1,369
Interest expense	(14,160)	(13,477)	(7,136)
Loss from equity method investments	(22,389)	(23,037)	(8,237)
Gain from change in fair value of warrant liability	0	688	147
Gain (loss) from change in fair value of derivative liability	1	8,056	(6,392)
Total other expense, net	(35,619)	(26,460)	(20,249)
Net loss	$ (141,447)	$ (162,141)	$ (116,389)
Net loss per share, basic and diluted (in dollars per share)	$ (1.76)	$ (2.14)	$ (1.81)
Weighted average number of common shares used in loss per share computation, basic and diluted	80,165,402	75,879,208	64,211,958